In terms of provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Windlas Biotech has informed that grant of 3,07,750 stock options has been approved by the Nomination and Remuneration Committee of Directors of the Company on 17th October, 2023, and the details are enclosed.
The above information is a part of company’s filings submitted to BSE.